Benzylaminated dextran-modified hydrogels: a long-term bioactive TGF-beta1 carrier

Area of Science:

• Biomaterials Science
• Tissue Engineering
• Drug Delivery

Background:

• Transforming growth factor beta 1 (TGFβ1) is crucial for regulating tissue repair.
• Achieving sustained, localized delivery of bioactive TGFβ1 remains a challenge in regenerative medicine.

Purpose of the Study:

• To develop dextran-based hydrogels capable of long-term immobilization and controlled release of bioactive TGFβ1.
• To investigate the impact of benzylaminated dextran (DMCB) conjugation on TGFβ1 retention and bioactivity.

Main Methods:

• Synthesis of highly porous dextran hydrogels with varying amounts of immobilized benzylaminated dextran (DMCB).
• In vitro assessment of TGFβ1 desorption from unmodified and DMCB-modified hydrogels over 21 days.
• Analysis of TGFβ1 release mechanisms (ionic vs. nonionic interactions) based on DMCB conjugation levels.
• Evaluation of in situ TGFβ1 bioactivity using a TGFβ-sensitive luciferase reporter gene assay.

Main Results:

• DMCB-modified hydrogels demonstrated significantly reduced TGFβ1 desorption (40-60%) compared to unmodified hydrogels (80-90%).
• TGFβ1 release mechanisms transitioned from ionic to nonionic interactions with increasing DMCB conjugation.
• Weakly DMCB-modified hydrogels provided superior long-term sequestration of bioactive TGFβ1, leading to enhanced reporter gene signaling.

Conclusions:

• Biocompatible, functionalized dextran hydrogels can achieve long-term retention of bioactive TGFβ1.
• Hydrogel modification with DMCB offers tunable control over TGFβ1 release kinetics and bioactivity.
• These functionalized hydrogels show potential as scaffolds for stimulating and regulating human tissue repair.